Demonstrates an ultrasensitive immunosensor for prostate-specific antigen, indicating a significant advancement in cancer biomarker detection.
Early detection of cancer biomarkers is crucial for improving patient survival rates. Herein, a highly sensitive label-free electrochemical immunosensor for prostate-specific antigen (PSA) was constructed based on in situ grown Ag₂S nanoparticle-decorated MoS₂ nanosheets (Ag₂S@MoS₂). The Ag₂S@MoS₂ nanocomposite synergistically combined the large surface area of MoS₂ with the high conductivity of Ag₂S, significantly amplifying the electroactive surface area and enhancing electron transfer. Upon formation of the insulating PSA-antibody immunocomplex, electron transfer was hindered, leading to a measurable current decrease. Under the optimal conditions, the sensor demonstrated a wide logarithmic linear range from 0.5 pg mL⁻¹ to 50 ng mL⁻¹ and an ultralow detection limit of 0.17 pg mL⁻¹ (based on 3σ/S). More importantly, the immunosensor demonstrated high selectivity, reproducibility, and, crucially, reliable accuracy in the detection of PSA in spiked human serum samples. This work not only provided a highly sensitive tool for PSA detection but also established a versatile and powerful sensing platform based on synergistic interface engineering, with broad potential for the detection of other disease biomarkers.
No takes yet. Share an insight, caveat, or question.
Dai et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: